Simtuzumab
As of the edition of 20 October 2026, Simtuzumab is an antibody: stopped in 2017; acts on LOXL2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2017
- Kind
- Antibody
- Registered trials
- 13, 5 stopped early
- Disease areas
- Digestive system; Cancer; Lungs and airways; Blood and lymph; Hormones; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Simtuzumab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| LOXL2 | Lysyl oxidase homolog 2 | Q9Y4K0 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 11 | 6 | 0 | 5 |
| All trials | 13 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Gilead Sciences | Lead sponsor of trials | 2010 to now |